Stronger inhibition of gastric acid secretion by lafutidine, a novel H_2 receptor antagonist, than by the proton pump inhibitor lansoprazole  

作　　者：Hatsushi Yamagishi Tomoyuki Koike Shuichi Ohara Toru Horii Ryousuke Kikuchi Shigeyuki Kobayashi Yasuhiko Abe Katsunori Iijima Akira Imatani Kaori Suzuki Takanori Hishinuma Junichi Goto Tooru Shimosegawa 

机构地区：[1]Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai 9808574, Japan [2]Division of Clinical Pharmacy, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai 9808574, Japan [3]Division of Pharmacotherapy, Tohoku University Graduate School of Pharmaceutical Sciences, and Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai 9808574, Japan

出　　处：《World Journal of Gastroenterology》2008年第15期2406-2410,共5页世界胃肠病学杂志（英文版）

摘　　要：AIM: To compare the antisecretory activity and plasma drug concentrations of a single oral dose of 10 mg lafutidine, a novel H2 receptor antagonist, with those of the proton pump inhibitor lansoprazole (LPZ) 30 mg. METHODS: Ten volunteers without H pylori infection participated in this crossover study comparing lafutidine 10 mg with LPZ 30 mg. Intragastric pH was monitored for 6 h in all participants, and blood samples were collected from four randomly selected individuals after single-dose administration of each drug. RESULTS: The median intragastric pH was significantly higher in individuals who received lafutidine 10 mg than in those who received LPZ 30 mg 2, 3, 4, 5, and 6 h after administration. Maximal plasma drug concentration was reached more promptly with lafutidine 10 mg than with LPZ 30 mg. CONCLUSION: In H pylori-negative individuals, gastric acid secretion is more markedly inhibited by lafutidinethan by LPZ.AIM： To compare the antisecretory activity and plasma drug concentrations of a single oral dose of 10 mg lafutidine, a novel H2 receptor antagonist, with those of the proton pump inhibitor lansoprazole （LPZ） 30 mg. METHODS： Ten volunteers without H pylori infection participated in this crossover study comparing lafutidine 10 mg with LPZ 30 mg. Intragastric pH was monitored for 6 h in all participants, and blood samples were collected from four randomly selected individuals after single-dose administration of each drug. RESULTS： The median intragastric pH was significantly higher in individuals who received lafutidine 10 mg than in those who received LPZ 30 mg 2, 3, 4, 5, and 6 h after administration. Maximal plasma drug concentration was reached more promptly with lafutidine 10 mg than with LPZ 30 mg. CONCLUSION： In H pylori-negative individuals, gastric acid secretion is more markedly inhibited by lafutidinethan by LPZ.

关 键 词：LAFUTIDINE LANSOPRAZOLE H2 receptor antagonists Proton pump inhibitors Antisecretory activity 

分 类 号：R571[医药卫生—消化系统]